---
title: "Bremelanotide"
canonical_url: https://peptidelibrary.app/library/bremelanotide
description: "FDA-approved melanocortin agonist (Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Bremelanotide

Bremelanotide (also called Vyleesi or PT-141) is an FDA-approved melanocortin agonist. Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist derived from melanotan II, with activity across MC1R, MC3R and MC4R and the greatest clinical relevance at MC4R. Its mechanism is central rather than vascular: MC4R activation in hypothalamic and limbic circuits modulates dopaminergic pathways governing sexual desire and excitation.

FDA-approved melanocortin agonist (Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

Also known as: Vyleesi, PT-141, Bremelanotide acetate.

## Classification

- Type: FDA-approved melanocortin agonist
- Mechanism class: Melanocortin receptor agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist derived from melanotan II, with activity across MC1R, MC3R and MC4R and the greatest clinical relevance at MC4R. Its mechanism is central rather than vascular: MC4R activation in hypothalamic and limbic circuits modulates dopaminergic pathways governing sexual desire and excitation. This distinguishes it from PDE5 inhibitors, which act peripherally on smooth muscle blood flow and address arousal mechanics rather than desire. Because it is dosed on demand and acts on central motivational circuits, the pharmacological target is the desire pathway itself. Transient blood pressure elevation and nausea reflect its residual activity at other melanocortin receptors.

Targets: MC4R, MC3R.

Origin: Cyclic heptapeptide analog of α-MSH; same peptide as research-chem PT-141.

## Properties

- Molecular formula: C50H68N14O10
- Molecular weight: 1,025.2 g/mol
- CAS number: 189691-06-3
- Half-life: ~2.7 hours
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 2
- Controlled human trials: 2
- Preclinical sources: 0

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. VYLEESI (bremelanotide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Premenopausal women with acquired, generalised hypoactive sexual desire disorder. Hypoactive sexual desire disorder [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf)
2. NCT02333071 — Study to Evaluate the Efficacy and Safety of Bremelanotide in Premenopausal Women With HSDD. Controlled human trial. Population: Premenopausal women with hypoactive sexual desire disorder (n=723). Sexual desire and related distress [Source](https://clinicaltrials.gov/study/NCT02333071)
3. NCT02338960 — Study to Evaluate the Efficacy and Safety of Bremelanotide in Premenopausal Women With HSDD. Controlled human trial. Population: Premenopausal women with hypoactive sexual desire disorder (n=714). Sexual desire and related distress [Source](https://clinicaltrials.gov/study/NCT02338960)

### Registered trials

- [NCT02333071](https://clinicaltrials.gov/study/NCT02333071)
- [NCT02338960](https://clinicaltrials.gov/study/NCT02338960)

## Safety

Side effects: Nausea; Flushing; Injection-site reactions; Headache; Transient blood-pressure rise.

Risks: Not for cardiovascular disease / uncontrolled hypertension; Focal hyperpigmentation.

Human safety basis: FDA prescribing information

## Regulatory status

Bremelanotide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### What is Bremelanotide?

FDA-approved melanocortin agonist (Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist derived from melanotan II, with activity across MC1R, MC3R and MC4R and the greatest clinical relevance at MC4R. Its mechanism is central rather than vascular: MC4R activation in hypothalamic and limbic circuits modulates dopaminergic pathways governing sexual desire and excitation.

### What are the side effects of Bremelanotide?

Side effects recorded for Bremelanotide from its prescribing information include nausea, flushing, injection-site reactions, headache and transient blood-pressure rise. Research-grade vials sold online are not the licensed product. This is reference information, not medical advice.

### How does Bremelanotide work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist derived from melanotan II, with activity across MC1R, MC3R and MC4R and the greatest clinical relevance at MC4R. Its mechanism is central rather than vascular: MC4R activation in hypothalamic and limbic circuits modulates dopaminergic pathways governing sexual desire and excitation.

### Is Bremelanotide FDA approved?

Yes. Bremelanotide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Bremelanotide?

Reported half-life for Bremelanotide is ~2.7 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Bremelanotide banned in sport?

Bremelanotide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Bremelanotide?

Compounds most often compared with Bremelanotide include Melanotan II, Afamelanotide, Setmelanotide and KPV. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [FDA label — Vyleesi](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)
- [Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder — Ann Pharmacother, 2020](https://pubmed.ncbi.nlm.nih.gov/31893927/)
- [Safety Profile of Bremelanotide Across the Clinical Development Program — J Womens Health (Larchmt), 2022](https://pubmed.ncbi.nlm.nih.gov/35147466/)
- [The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results — J Womens Health (Larchmt), 2021](https://pubmed.ncbi.nlm.nih.gov/33538638/)
- [An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist — J Sex Med, 2006](https://pubmed.ncbi.nlm.nih.gov/16839319/)
- [Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder — J Sex Res, 2024](https://pubmed.ncbi.nlm.nih.gov/36809187/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
